Literature DB >> 25641317

An overview of polymyositis and dermatomyositis.

Andrew R Findlay1, Namita A Goyal, Tahseen Mozaffar.   

Abstract

Polymyositis and dermatomyositis are inflammatory myopathies that differ in their clinical features, histopathology, response to treatment, and prognosis. Although their clinical pictures differ, they both present with symmetrical, proximal muscle weakness. Treatment relies mainly upon empirical use of corticosteroids and immunosuppressive agents. A deeper understanding of the molecular pathways that drive pathogenesis, careful phenotyping, and accurate disease classification will aid clinical research and development of more efficacious treatments. In this review we address the current knowledge of the epidemiology, clinical characteristics, diagnostic evaluation, classification, pathogenesis, treatment, and prognosis of polymyositis and dermatomyositis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  dermatomyositis; inclusion-body myositis; inflammatory myopathy; myositis-specific autoantibodies; polymyositis

Mesh:

Substances:

Year:  2015        PMID: 25641317     DOI: 10.1002/mus.24566

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  37 in total

1.  Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy.

Authors:  Kevin E McElhanon; Nicholas Young; Jeffrey Hampton; Brian J Paleo; Thomas A Kwiatkowski; Eric X Beck; Ana Capati; Kyle Jablonski; Travis Gurney; Miguel A Lopez Perez; Rohit Aggarwal; Chester V Oddis; Wael N Jarjour; Noah Weisleder
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 2.  Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications.

Authors:  Raul E Ruiz-Lozano; Fabiola Velazquez-Valenzuela; Mariana Roman-Zamudio; Salma K Andrade-Leal; Alejandro Rodriguez-Garcia
Journal:  Rheumatol Int       Date:  2021-10-21       Impact factor: 2.631

Review 3.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

Review 4.  Corticosteroids in Myositis and Scleroderma.

Authors:  Anna Postolova; Jennifer K Chen; Lorinda Chung
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

5.  Elevated Fractalkine (CX3CL1) Levels in the Trigeminal Ganglion Mechanically Sensitize Temporalis Muscle Nociceptors.

Authors:  Brian E Cairns; Melissa O'Brien; Xu-Dong Dong; Parisa Gazerani
Journal:  Mol Neurobiol       Date:  2016-05-21       Impact factor: 5.590

6.  [Clinical, pathological and genetic studies of two cases of childhood-onset nemaline myopathy].

Authors:  Kun Huang; Yi-En Luo; Qiu-Xiang Li; Hui-Qian Duan; Fang-Fang Bi; Huan Yang; Yue-Bei Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-10

7.  Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.

Authors:  S Ahmed; S Chakka; J Concha; R Krain; R Feng; V P Werth
Journal:  Br J Dermatol       Date:  2019-09-08       Impact factor: 9.302

8.  Dysphonia and dysphagia as early manifestations of autoimmune inflammatory myopathy.

Authors:  Samuel F Weinreb; Krzysztof Piersiala; Alexander T Hillel; Lee M Akst; Simon R Best
Journal:  Am J Otolaryngol       Date:  2020-10-03       Impact factor: 1.808

9.  Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.

Authors:  Sooraj John; Scott J Antonia; Trevor A Rose; Robert P Seifert; Barbara A Centeno; Aaron S Wagner; Ben C Creelan
Journal:  J Immunother Cancer       Date:  2017-07-18       Impact factor: 13.751

10.  Case Report: Elevated CPK, an indicator of idiopathic inflammatory myopathy?

Authors:  Hina N Khan; Usman Jilani; Shitij Arora
Journal:  F1000Res       Date:  2016-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.